Background
Methods to promote bladder health and prevent lower urinary tract symptoms (LUTS) are poorly understood and strategies for decreasing risk of LUTS across the lifespan of girls and women are lacking. In order to better understand the impact of bladder health promotion and LUTS prevention strategies, valid measures for assessing bladder health are urgently needed. Historically, and like most medical conditions, bladder health has been assumed through the presence or absence of symptoms. Existing instruments have been primarily designed to measure LUTS and assess impact of interventions in clinical populations or the burden of disease in epidemiologic studies. While reports of “normative data” and “healthy function” have been published, these are limited by the fact that the study populations are typically poorly characterized with respect to bladder health and described as “normal”, “healthy”, or “asymptomatic” based purely on the absence of LUTS [
1‐
3]. Additionally, while there are numerous terms and definitions to describe bladder disease, a definition and measure of bladder health did not previously exist. Thus, a true estimate of women’s bladder health in the general population is currently not attainable.
The Prevention of Lower Urinary Tract Symptoms (PLUS) Research Consortium was established in 2015 with the primary charge of identifying and promoting bladder health (BH) [
4]. By employing a rigorous prevention-based research agenda, the ultimate goal is to understand how to promote and preserve bladder health and prevent LUTS over the life course of girls and women [
5,
6]. Essential toward this aim is an assessment of the distribution of bladder health in the general population. An initial step in the process was to establish a formal definition of bladder health for use in the development of a valid measure [
7]. Consistent with the World Health Organization’s definition of health [
8]. The PLUS Consortium conceptualizes bladder health as
“a complete state of physical, mental, and social well-being related to bladder function, and not merely the absence of lower urinary tract symptoms (LUTS). Healthy bladder function permits daily activities, adapts to short term physical or environmental stressors, and allows optimal well-being (e.g., travel, exercise, social, occupational or other activities)” [
9].
Measuring degrees of bladder health in a variety of settings requires a valid instrument, ideally self-administered, that can capture a spectrum from very healthy to very unhealthy. The PLUS bladder health item pool was generated using expert opinion, review and adaptation of existing instruments, and drafting of novel items to assess the elements of our conceptual model of bladder health. This content valid item pool is referred to as the Bladder Health Instrument (BHI), with the aim of further development and evaluation to result in a Bladder Health Scale (BHS). The BHI items and language were further refined by cognitive evaluation with community dwelling women and review of focus group data, as the initial step in scale development [
10]. The primary objective of this paper is to describe the methodology employed by the PLUS Research Consortium for scale development and further scale evaluation, including: (1) assess the reliability and validity of the PLUS-BHI for measurement of bladder health among adult women and (2) evaluate effects of mode of administration of the PLUS-BHI in order to create a scale that is mode agnostic. This will support its use in future research in population-based national studies and future prevention trials.
Discussion
Challenges in validating “health”
Many health care providers have spent their clinical and research careers studying and treating women with urinary symptoms as evidenced by the greater than 50 validated instruments to assess symptoms and quality of life impact in women with LUTS [
43]. Previous efforts have focused on defining and treating the disease and not on prevention. The long-term goal of the PLUS Consortium is to decrease the incidence and prevalence of LUTS in women by identifying and then modifying risk and protective factors. Central to this goal is the ability to measure bladder health across a woman’s life course. The PLUS-BHI development and validation described in this manuscript is considered by the PLUS Consortium to be the cornerstone of future efforts in LUTS prevention research.
Critical to the development of the PLUS-BHS for research purposes is having a definition for bladder health [
9,
44]. One of the greatest challenges of developing the PLUS-BHS is that we are measuring an abstract theoretical construct such as bladder sensation (a component of bladder health) by asking specific questions that are intended to capture the range of meaning of normal and abnormal “bladder sensation” [
45]. We recognize that the questions about bladder function are likely to be interpreted in numerous ways by respondents due to the inability to discriminate between the responses. This is compounded by the reality that the presence of bladder symptoms in women are often considered a “normal” part of aging or secondary to childbirth. As a result, a woman might choose a response that describes her urinary leakage accurately, but attribute minimal disruption in her quality of lifestyle or bother to the symptom because she has been conditioned to believe it is normal. In addition, some LUTS are episodic such as stress incontinence or urinary tract infection symptoms yet are contributors or detractors from bladder health. Additional challenges to measuring overall bladder health relate to the fact that responses to questions can vary based on whether or not a woman is experiencing symptoms at the time of the instrument completion or has ever experienced any symptoms across her life course. Finally, it is challenging to design a measurement of health that is generalizable and interpretable across populations, the life course and settings. To address these issues, we use multiple samples across population and bladder health states and include a clinical interview and review of specific bladder testing by a variety of judges to improve use of the instrument across contexts.
Strengths and limitations
One of the primary intended uses of the validated PLUS-BHS is to establish a U.S. general population estimate of women’s bladder health, across the life course. To ensure the PLUS-BHS is valid for this inference it is essential to validate using a national general population sample of women. Some of the challenges in conducting national population research is the identification of a representative sample frame, minimizing the well-known problem of coverage error. With survey methods sampling, the DSF with household level enumeration of every known mailing address within the U.S. is the address base sampling frame with the lowest coverage error that exists. The use of random assignment of both general population participants as well as, general clinical participants to the multiple modes (PAPI, CASI and within CASI Web primary as well as push to web) allows a valid and unconfounded comparison of differences in both response rate, item-response as well as distributional differences across mode. The inclusion of clinical samples using community based recruitment allows a clinical evaluation of women across the spectrum of potential bladder health. The inclusion of objective clinical test data provides the “hard ratings” required as a standard of evidence for valid inference with the intended use of the PLUS-BHS. A major strength of our validation work is the inclusion and evaluation of women during the postpartum period. While we would not expect women’s bladder health to be considered stable during pregnancy, we expect the postpartum period to be a factor in women’s bladder health over their lifetime.
While the goal of the PLUS-BHS is to be used across the female lifespan including adolescent girls and adult women, this initial validation was limited to English speaking women ≥ 18 years of age. The development of a similar instrument for adolescents and Spanish speaking females is underway and will be facilitated by the outcomes of the VIEW study. Since the instrument is specifically designed for women, who have different lower urinary tract anatomy and symptoms when compared to men or transgender women, this instrument is not intended for use with males or adolescent females. Lastly, the PLUS-BHI is only tested for clinical research in ambulatory women; thus, women who have functional and neurogenic LUTS are not included in the spectrum of bladder health assessed by the PLUS-BHI. The questions and answer stems might not be appropriate in this population and would need further testing to determine their ability to discriminate bladder health from bladder disease in certain populations.
The VIEW study includes women from the general population and from those recruited around clinical centers, those who are recently postpartum and who attend clinical practices for health care. While this range of recruitment can be a strength of the study to assure a wide range of contexts, it is also possible that the distribution of bladder health may not be comparable between the populations. While clinical center recruitment was intentionally designed in order to capture the full spectrum of very healthy to very unhealthy, the screening instrument we used (the PPBC) may not accurately discriminate across the true severity of disease and does not address impact of symptoms. Similarly, validated questionnaires were not used to stratify women according to type of LUTS for inclusion in the clinical examination. It is also possible that women recruited from clinical practices, specifically specialty practices (e.g. urology, urogynecology) and with self-reported severe symptoms may be fundamentally different than women who may have symptoms but who do not seek out care for LUTS. As a result, the PLUS-BHS may discriminate between participants with similar LUTS who have different expectations for their bladder health. Modifications to the scoring of the PLUS-BHS may need to be made for general, clinical and postpartum populations and the PLUS-BHS would not be as generalizable as desired.
The VIEW study participants are randomized to the use of paper or computer instruments in order to evaluate potential mode effect on items and subsequently develop a scale that is mode agnostic. While we aim to have a mode agnostic instrument, we acknowledge that it may not be feasible to conduct population based research using CASI mode given systemic biases associated with women’s access to technology. Additionally, while the use of smartphones and technology has increased in many parts of the U.S., we anticipate differences in response rates by mode of administration across age groups and by socioeconomic status.
In conclusion, we present the rationale and approach to development and validation of a novel instrument for the measurement of bladder health in epidemiologic research. The scored bladder health scale will provide the foundation to assess the distribution of bladder health in women and girls within the United States and allow for future study of a variety of factors associated with bladder health. With this foundational instrument developed, future iterations and adaptations will be possible to include adolescent and Spanish-speaking females and pregnant populations. Additional efforts in the future will focus on assessing sensitivity to change and minimum important differences for use in intervention studies. These data will inform future intervention trials in the promotion of bladder health and prevention of lower urinary tract symptoms in women across the life course.
Acknowledgements
The PLUS Research Consortium (aka Group Authorship) consists of the following members who contributed to this work. Linda Brubaker, MD, MS; Elizabeth Mueller, MD, MSME; Colleen Fitzgerald, MD, MS; Cecilla Hardacker, RN, MSN; Jennifer Hebert-Beirne, PhD; Missy Lavender, MBA; David Shoham, PhD; Alayne D. Markland, DO, MSc; Tamera Coyne-Beasley, MD, MPH, FAAP, FSAHM; Kathryn L. Burgio, PhD; Cora E. Lewis, MD; Gerald McGwin, PhD; Camille P. Vaughan, MD, MS; Beverly R. Williams, PhD; Emily S. Lukacz, MD; Sheila Gahagan, MD, MPH; Daphne Y. LaCoursiere, MD, MPH; Jesse Nodora, DrPH; Janis M. Miller, PhD, MSN; Lawrence Chin-I An, MD; Lisa Kane Low, PhD, MS, CNM; Diane K. Newman, DNP, CRNP; Amanda Berry, MSN, CRNP; C. Neill Epperson, MD; Heather Klusaritz, PhD, MSW; Kathryn H. Schmitz, PhD; Ariana L. Smith, MD; Ann E. Stapleton, MD; Jean F. Wyman, PhD; Siobhan Sutcliffe, PhD; Aimee S. James, PhD; Jerry Lowder, MD, MSc; Melanie R. Meister, MD, MSCI: Leslie M. Rickey, MD; Deepa Camenga, MD, MS; Shayna D. Cunningham, PhD; Jessica Lewis, PhD.; Tamara G. Bavendam MD, MS; Bernard L. Harlow, PhD and Kyle Rudser, PhD; Sonya S Brady, PhD; John Connett, PhD; Haitao Chu, MD, PhD; Melissa L. Constantine, PhD, MPaff; Cynthia S. Fok, MD, MPH; Todd Rockwood, PhD; Mary H. Palmer, PhD, RN.
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.